Abattis Bioceuticals(ATTBF)
$0.000.00 (0.00%)
ATTBF
Abattis Bioceuticals financials statements
$0.00
At close:0.00 (0.00%)
Abattis Bioceuticals (ATTBF) Ratios
176 Followers
Abattis Bioceuticals Ratios
ATTBF's free cash flow for Q4 2019 was C$-1.10M. For the 2019 fiscal year, ATTBF's free cash flow was decreased by C$-5.04M and operating cash flow was C$3.93M. See a summary of the company’s cash flow.
| Ratios | Sep 19 | Sep 18 | Sep 17 |
|---|---|---|---|
| Liquidity Ratios | |||
| Current Ratio | 0.73 | 34.51 | 1.55 |
| Quick Ratio | 0.68 | 34.41 | 1.55 |
| Cash Ratio | 0.41 | 13.41 | 1.20 |
| Solvency Ratio | -0.34 | -257.21 | -17.17 |
| Operating Cash Flow Ratio | 1.92 | -27.31 | -2.78 |
| Short-Term Operating Cash Flow Coverage | 6.64 | 0.00 | 0.00 |
| Net Current Asset Value | C$ -4.99M | C$ 10.16M | C$ 239.86K |
| Leverage Ratios | |||
| Debt-to-Assets Ratio | 0.08 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.14 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.12 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.74 | 0.99 | 0.79 |
| Debt Service Coverage Ratio | -1.98 | -4.73 | -1661.02 |
| Interest Coverage Ratio | -80.16 | -4.01 | -2091.91 |
| Debt to Market Cap | 0.13 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.01 | 0.00 |
| Net Debt to EBITDA | 0.15 | 0.23 | 0.10 |
| Profitability Margins | |||
| Gross Profit Margin | 67.62% | 77.37% | 0.00% |
| EBIT Margin | -843.89% | -875805.50% | 0.00% |
| EBITDA Margin | -813.34% | -207095.93% | 0.00% |
| Operating Profit Margin | -1108.73% | -207542.23% | 0.00% |
| Pretax Profit Margin | -857.72% | -927614.02% | 0.00% |
| Net Profit Margin | -852.40% | -931940.11% | 0.00% |
| Continuous Operations Profit Margin | -857.72% | -927614.02% | 0.00% |
| Net Income Per EBT | 99.38% | 100.47% | 96.32% |
| EBT Per EBIT | 77.36% | 446.95% | 124.60% |
| Return on Assets (ROA) | -15.79% | -684.35% | -630.47% |
| Return on Equity (ROE) | -27.46% | -679.12% | -500.69% |
| Return on Capital Employed (ROCE) | -27.58% | -156.57% | -824.58% |
| Return on Invested Capital (ROIC) | -25.05% | -156.57% | -794.82% |
| Return on Tangible Assets | -68.98% | -684.35% | -630.47% |
| Earnings Yield | -26.98% | -135.47% | -26.41% |
| Efficiency Ratios | |||
| Receivables Turnover | 2.30 | 0.00 | 0.00 |
| Payables Turnover | 0.53 | 0.01 | 0.00 |
| Inventory Turnover | 0.43 | 0.06 | 0.00 |
| Fixed Asset Turnover | 0.47 | 0.01 | 0.00 |
| Asset Turnover | 0.02 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.08 | 0.00 | 0.00 |
| Cash Conversion Cycle | 310.19 | -37211.88 | 0.00 |
| Days of Sales Outstanding | 158.61 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 846.07 | 5868.71 | 0.00 |
| Days of Payables Outstanding | 694.49 | 43080.60 | 0.00 |
| Operating Cycle | 1004.68 | 5868.71 | 0.00 |
| Cash Flow Ratios | |||
| Operating Cash Flow Per Share | 0.02 | -0.03 | -0.01 |
| Free Cash Flow Per Share | 0.01 | -0.03 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | 1.86 | -35.42 | -2.84 |
| Capital Expenditure Coverage Ratio | 1.86 | -35.42 | -2.84 |
| Operating Cash Flow Coverage Ratio | 6.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 26.37 | -989.06 | 0.00 |
| Free Cash Flow Yield | 38.59% | -14.78% | -5.72% |
| Valuation Ratios | |||
| Price-to-Earnings (P/E) Ratio | -3.71 | -0.74 | -3.79 |
| Price-to-Sales (P/S) Ratio | 31.59 | 6879.26 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.02 | 5.01 | 18.96 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 2.59 | -6.76 | -17.48 |
| Price-to-Operating Cash Flow Ratio | 1.20 | -6.96 | -23.65 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | -0.00 | -0.03 |
| Enterprise Value Multiple | -3.73 | -3.09 | -5.32 |
| Enterprise Value | 10.83M | 53.52M | 28.38M |
| EV to EBITDA | -3.73 | -3.09 | -5.32 |
| EV to Sales | 30.33 | 6393.78 | 0.00 |
| EV to Free Cash Flow | 2.49 | -6.29 | -17.17 |
| EV to Operating Cash Flow | 1.15 | -6.46 | -23.22 |
| Tangible Book Value Per Share | -0.01 | 0.03 | 0.01 |
| Shareholders’ Equity Per Share | 0.02 | 0.04 | 0.01 |
| Tax and Other Ratios | |||
| Effective Tax Rate | 0.00 | -0.04 | 0.04 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.01 | -0.24 | -0.05 |
| Tax Burden | 0.99 | 1.00 | 0.96 |
| Interest Burden | 1.02 | 1.06 | 1.46 |
| Research & Development to Revenue | 0.00 | 3.45 | 0.00 |
| SG&A to Revenue | 8.34 | 1508.56 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 59.11 | 0.00 |
| Income Quality | -3.07 | 0.11 | 0.15 |
Currency in CAD
